News
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Eckert & Ziegler: Further Increase in Earnings in the First Half of 2025
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
EQS-News: Eckert & Ziegler: Implementation of the Share Split by Issuing Bonus Shares to Be Effective on 15 August 2025
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: MEDICLIN reports positive interim results for the first half of 2025
EQS-News: MEDICLIN reports positive interim results for the first half of 2025
Sensorion Announces Its Participation In Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
-
Revenue grew 15% year-over-year to
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Formycon invites to conference call on 2025 half-year results and announces participation in international investor conferences in the 3rd quarter of 2025
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
EQS-News: Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
EQS-News: Eckert & Ziegler: Capital Increase Entered in the Commercial Register. Share Split in Preparation.
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: Abivax Announces Launch of Public Offering
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
EQS-News: Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG
Evolva Holding SA: Update about earn-out from Danstar
Evolva Holding SA: Update about earn-out from Danstar
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
Lonza Delivers Strong H1 2025 Performance and Upgrades 2025 Full-Year CDMO Sales and Margin Outlook
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
EQS-News: Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Humana Accelerates Efforts to Eliminate Prior Authorization Requirements to Ensure a Faster, More Seamless Process
Humana Inc., a leading health and well-being company, today announced accelerated efforts to approve care requests as quickly as possible and reduce the administrative burden for physicians